cjc-1295 & ipamorelin: and Ipamorelin Peptide Injection Capsulated BPC-157 Arginate Salt 2023_November Contains:1 sterile vial x 238 mg/0.0084 oz. vials.

cjc-1295 & ipamorelin: and Ipamorelin Peptide Injection Capsulated BPC-157 Arginate Salt 2023_November Contains:1 sterile vial x 238 mg/0.0084 oz. vials.

Capsulated BPC-157 Arginate Salt · Disguised Alpha

Among these, ipamorelin is unique in acting on the GHS-R1a (ghrelin) receptor rather than the GHRH receptor, producing a complementary GH release stimulus that is additive when combined with GHRH-pathway agonists in research models.[1][15] Phase I human pharmacokinetic data (Gobburu et al., 1999) established linear PK with a terminal half-life of ~2 hours and SC₅₀ of 214 nmol/L.[2] Mechanism of Action Mechanism of Action Ipamorelin activates the GHS-R1a (ghrelin receptor) on pituitary somatotroph cells with an in vitro EC₅₀ of 1.3 ± 0.4 nmol/L and in vivo ED₅₀ of 2.3 nmol/kg (swine)

2023_November

Contains:1 sterile vial x 238 mg/0.0084 oz. vials.

Brain Sciences, 5(4), 518-554